臺灣博碩士論文加值系統

玻尿酸是體內的多醣類高分子聚合物，具有親水性與黏彈性，其製備方法有二種：一是由動物組織中萃取，主要來源是人類臍帶、雞冠和牛眼玻璃體等；二是微生物醱酵方法，主要是存在鏈球菌(streptococci)莢膜中。在業界所選用的原料中，以雞冠為主要來源，經萃取及純化後而得，但在純化過程常用到氯仿去除雜質，而氯仿屬於列管中化學毒性物質，具有毒性高、單價高的缺點。故本篇論文主要以不同的蛋白質沉澱劑列出作為變因，找出是否有其他試劑可以取代目前常用的物質，並探討純化後產品之產率及物理性質。結果顯示控制組所得到玻尿酸產率為0.661%、純度為每克粗萃取物中含有0.201 mg的玻尿酸、黏度為5.04 cps、蛋白質含量為0.064 mg/mL，由上述結果得知控制組純化出的玻尿酸產物其物性和氯仿有相似的結果，故控制組用來取代氯仿，不但可以節省成本還可達到減少環境污染之效果。

Many pharmaceutical hyaluronic acid (HA) products have been prepared from umbilical cord, synovial fluid, skin and rooster combs as well as microbial fermentation. At present, most of HA is prepared from rooster combs. The HA extract has been purified using precipitant to remove impurities and obtain with product desirable purity. Because chloroform which precipitant used in this purification procedure is a high toxic organic solvent and higher cost, the aim of this study is to search for other protein precipitants to replace chloroform, and to investigate the effect of different precipitants on the yield and quality of HA extracted from rooster combs. In this study, the result shows: the yield of hyaluronic acid is 0.661%、purity is 0.201 mg HA/g extract、viscosity is 5.04 cps and the amount of protein is 0.064 mg/mL in the control. The products obtained in this study were as the same as the product using chloroform as a precipitant. Instead of using chloroform, applying these deproteinizing agents not only reduces costs, but also decreases environmental pollution.

1. 前言1
2. 文獻回顧2
2.1 玻尿酸發現2
2.2 玻尿酸之結構2
2.2.1 玻尿酸一級與二級結構2
2.2.2 玻尿酸三級結構3
2.3 玻尿酸之生理機制4
2.3.1 玻尿酸之生化合成4
2.3.2玻尿酸之異化作用4
2.4 玻尿酸物化特性8
2.4.1 玻尿酸水膠之膨潤性8
2.4.2 玻尿酸之黏彈性9
2.5 玻尿酸萃取來源10
2.5.1 動物組織10
2.5.2 微生物來源11
2.6 玻尿酸純度分析11
2.7 蛋白質分離-沉澱法12
2.8 有機溶劑之選擇14
3. 材料與方法18
3.1 材料18
3.2 實驗器材與儀器設備19
3.3 雞冠玻尿酸的萃取19
3.3.1 粗萃取液製備21
3.3.2 第一次去除雜蛋白純化方法21
3.3.3 第二次雜蛋白去除之溶劑萃取法24
3.4分析方法25
3.4.1 己醣醛酸測定25
3.4.2 玻尿酸之蛋白質含量分析26
3.4.2.1試劑配製26
3.4.2.2實驗流程26
3.4.3 玻尿酸之黏度性質測定27
3.4.4 玻尿酸之高效能液相層析儀(HPLC)純度分析27
3.4.5 玻尿酸之離子交換層析28
3.4.6 玻尿酸之核磁共振(nuclear magnetic resonance, NMR)分析28
4. 結果與討論29
4.1 不同蛋白質沉澱方法對玻尿酸粗萃取物產率的影響29
4.2 不同蛋白質沉澱方法對玻尿酸粗萃取物純度的影響29
4.3 不同蛋白質沉澱方法對玻尿酸粗萃取物黏度的影響30
4.4 不同蛋白質沉澱方法對玻尿酸粗萃取物蛋白質含量的影響30
4.5 高效能液相層析儀分析31
4.6 玻尿酸之離子交換層析31
4.7 玻尿酸核磁共振分析33
5. 結論42
參考文獻43

圖目錄

圖2.1 玻尿酸之ㄧ級結構4
圖2.2 雙醣單位之間的糖苷鍵4
圖2.3 雙醣單位間的氫鍵5
圖2.4 玻尿酸分子在溶液中的三度空間型態6
圖3.1 實驗流程圖20
圖4.1 不同蛋白質沉澱劑對玻尿酸粗萃取物產率影響之比較34
圖4.2 不同蛋白質沉澱劑對玻尿酸粗萃取物純度之比較35
圖4.3 不同蛋白質沉澱劑對玻尿酸萃取物黏度影響之比較36
圖4.4 不同蛋白質沉澱劑對玻尿酸粗萃取物蛋白質含量之比較37
圖4.5 不同蛋白質沉澱劑對玻尿酸粗萃取物高效能液相層析儀分析結果之比較38
圖4.6 玻尿酸控制組之離子交換層析圖39
圖4.7 核磁共振分析之氫光譜圖(A)Control, (B)Standard40
圖4.8 核磁共振分析之碳光譜圖(A)Control,(B)Mytilus galloprovincialis (C)Mytilus galloprovincialis 45-110 ppm41

表目錄

表2.1 常用的沉澱蛋白質之方法15
表2.2 Hofmeister Series蛋白質沉澱劑16
表2.3 常用有機溶劑之log P值17

1.王奕嵐。1997。透明質酸還原端氧化衍生物之應用。碩士論文。陽明大學。台灣。台北。
2.朱兆秀。2005。利用鏈球菌發酵生產透明質酸。化工技術148：165-172。
3.汪家政、范明。2000。.蛋白質技術手冊。科學出版社。北京。
4.吳昌至。2002。雞冠與豬眼球中透明質酸和膠原蛋白之抽取及純化。碩士論文。中興大學。台灣。台中。
5.吳鎮宇。2004。微生物發酵生產透明質酸製程之探討。碩士論文。南台科技大學。台灣。台南。
6.黃定國。2001。透明質酸之開發與應用。菌種保存及研究簡訊14:1-9。
7.陳樹人、黃煒智。2004。玻尿酸發酵與分離純化技術。化工技術140：143-151。
8.蕭至君。2003。利用重組大腸桿菌生產透明質酸之研究。碩士論文。陽明大學。台灣。台北。
9.謝慧冰。2005。攪拌剪應力是透明質酸發酵放大設計之關鍵因素。碩士論文。成功大學。台灣。台北。
10.Alam, C. A., Seed, M. P. and Willougby, D. A. 1995. Angiostasis and vascular regression in chronic granulomatous inflammation induced by Diclofenac in combination with hyaluronan in mice. J. Pharm. Pharmacol. 47:407-412.
11.Bailey, J. E. and Oilis, D. F. 1986. Biochemical Engineering Fundamentals, 2nd ed., p.721, McGraw-Hill, New York.
12.Balazs, E. A. 1979. Ultrapure hyaluronic acid and the use therefore. US.Pat. 4141973.
13.Balazs, E. A. 1984. Hyaluronic acid:Its structure and use.Cosmetics & Toiletries magazine. 99:65-72.
14.Baker, S. A. and Young, N. M. 1966. Isolation of hyaluronic acid by gel filtration on agarose. Carbohydr. res. 2:363-370.
15.Bell, D. J., Hoare, M. and Dunnill, P. 1983. The Formation of Protein Precipitates and their Centrifugal Recovery. Adv. Biochem. Eng. Biotechnol. 26:1-72 .
16.Bitter, T. and Muir, H. M. 1962. A modified uronic acid carbazole reaction. Anal. Biochem. 4:330
17.Bjurstrom, E. 1985. Biotechnology: Fermentation and Downstream Processing. Chem. Eng. 92:126-158.
18.Bothner, H., and Wik, O. 1987. Rheology of hyaluronate. Acta Oto-Laryngol. 442:25-30.
19.Brown, M., Marriot, C., and Martin, G. P. 1995. The effect of hyaluronan in the ‘in vitro’ deposition of Diclofenac within the skin. Int. J. Tissue React. 17:33-37.
20.Casione, M. 1995. Blends of synthetic and natural polymers as drug delivery systems from growth hormone. Biomaterials. 16:569-576.
21.Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED). 2002. Placenta humana como materia prima farmace utica REGULACION No. 2/2002.
22.Fisher, R. R., Glatz, C. E. and Murphy, P. A. 1986. Effects of Mixing During Acid Addition on Fractionally Precipitated Protein. Biotechnol. Bioeng. 28:1056-1063 .
23.Englard, S. and Seifter, S. 1990. Precipitation Techniques. Meth. Enzymol. 182:285.
24.Fisher, R. R., C. E. Glatz, and P. A. Murphy. 1986. Effects of Mixing During Acid Addition on Fractionally Precipitated Protein. Biotechnol. Bioeng. 28:1056-1063 .
25.Fraser, J. R. E., Laurent, T.C., and Laurent, U.B.G. 1997. Hyaluronan:its nature, distribution, Functions and Turnover, J. Int. Med, 242:27-33.
26.Garcia, A. A., Bonen, M. R., Ramirez-Vick, J., Sadaka, M., and Vuppu, A. 1999. Bioseparation process sciencr. Blackwell Science, Malden, MA 178-229.
27.Hascall, V. C., and Laurent, T. C. 1997. Hyaluronan: Structure and physical properties. http://www.glycoforum.gr.jp.
28.Haxaire, K., Braccini, I., Milas, M., Rinaudo, M., and Pérez, S. 2000. Conformational behavior of hyaluronan in relation to its physical properties as probed by molecular modeling. Glycobiology. 10(6):587-594.
29.Hofmeister, F. 1890. Uber die Darstellung von Krystallisirtem Eiralbumin und die Krystallisirbarkeit Colloider Stoffe. Z. Physiol. Chem. 14:165-170.
30.Hollands, I. E., Gomez Barry, H., and Miyares, C. M. 2003. Biological model for test of the photoprotector action from human umbilical cord extract. Revista Cubana de Farmacia. 37(1), 203-208.
31.Iyer, H. V., and Przybycien, T. M. 1994. Protein Precipitation: Effects of Mixing on Protein Solubility. AlChE J. 40(2):349-360.
32.Jamal Alyoussef Alkrad, Yahya Meratani, Reinhard H.H. Neubert. 2002. New approaches for quantifying hyaluronic acid in pharmaceutical semisolid formulations using HPLC and CZE, J. Pharm. Biomed. Anal. 30, 913-919.
33.Johns, M. R., Goh, L. T., and Oeggerli, A. 1994. Effect of pH, agitation and aeration on hyaluronic acid production by Streptococcus zooepidemicus. Biotech. Letter. 16:507-512.
34.Karlsson, G., and Bergman, R. 2003. Determination of the distribution of molecular masses of sodium hyaluronate by high-performance anion exchange chromatography. J. Chromatogr. A 986(1): 67–72.
35.Koshiishi I., Takenouchi M., Hasegawa T., and Imanari T. 1998. Enzymatic Method for the Simu taneous Determination of Hyaluron and Chondroitin Sulfates Using High Performance Liquid Chromatography. Anal. Biochem. 265:49-54.
36.Kumar, A., Sahoo, B., Montpetit, A., Behera, S., Lockey R.F., and Mohapatra S.S. 2007. Development of hyluronic acid-Fe2O3 hybrid magnetic nanoparticles for targeted delivery of peptides. Nanomedicine: NBM 3: 132-137.
37.Lago, G., Oruña, L., Cremata, J. A., Pérez, C., Coto, G., Lauzan, E., and Kennedy, J.F. 2005. Isolation, purification and characterization of hyaluronan from human umbilical cord residues. Carbohydr Polym. 62:321-326.
38.Laane, C., Boeren, S., Vos, K., and Veeger, C. 1987. Rules for optimization of biocatalysis in organic solvents. Biotechnol. Bioeng. 30: 81-87.
39.Laurent, T. C.. 1987. Biochemistry of jyaluronan. Acta Otolaryngol (Stockh) suppl. 442: 7.
40.Laurent, T. C., and Fraser, J. R. E. 1992. Hyaluronan. FASEB J. 6:2397-2404.
41.Lowry, K. M., and Beavers, E. M. 1994. Thermal stability of sodium hyaluronate in aqueous solution. J. Biomed. Mater. Res. 28:1239.
42.Michaels, A. S., 1990. “Frontiers of Bioseparations Technology: Unsolved Problems and Novel Process Concepts,” Int. Conf. on Separations for Biotechnology, UK, 3-8.
43.Moris, J. E., Hoffman, A. S. and Fisher, R. R. 1993. Affinity precipitation of proteins by polyligands. Biotechnol. Bioeng. 41:991-997.
44.Nakayama, A., K. Kawamura, H. Shimada, A. Akaoka, I. Mita, M. Honjo, and Y. Furutani. 1987. Extracellular Production of Human Growth Hormone by Head Portion of the Prepropeptide Derived from Bacillus amyloliquefaciens Neutral Protease in Bacillus subtillis. J. Biotechnol., 5:171-180.
45.Niktari, M., S. Chard, P. Richardson, and M. Hoare. 1990. The Monitoring and Control of protein Purification and Recovery Processes. Int. Conf.on Separations for Biotechnology, UK, p. 622.
46.Nicola , V., and Francesca M. 2003. Purification and characterization of hyaluronic acid from the mollusc bivalve Mytilus galloprovincialis. Biochime. 85:619-625.
47.Nimrod, A. B., Greenman, D., Kanner, M., Landsberg and Beck, Y. 1998. Method of producing high molecular weight sodium hyaluronate byfermentation of Streptococcus. US. Pat. 4780414.
48.Oerther, S., Murin, A. C., Payan, E., Hubert, P., Presle, N., and Dexheimer, J. 2000. High interaction alginate–hyaluronate association by hyaluronate deacetylation for the preparation of efficient biomaterials. Biopolymers. 54(4): 273–281.
49.Oerther, S., Payan, E., Lapicque, F., Presle, N., Hubert, I., and Muller, S. 1999. Hyaluronate–alginate combination for the preparation of new biomaterials. Investigation of the behaviour in aqueous solutions. Biochim. Biophys. Acta. 1426(1):85-94.
50.Orvisky, E., Salter, L., Chabrecek, P., Novak, I., Kery, V., and Stancikova, M. 1992. Determination of hyaluronan molecular weight distribution by means of high performance size exclusion chromatography. J. Liq. Chromatogr. 15(18): 3203-3218.
51.Pisárčik, M., Bakoš, D., and Čeppan, M. 1995. Non-Newtonian properties of hyaluronic acid aqueous solution. Colloids and Surfaces. 97:197-202.
52.Rothstein, F. 1991. Production Scale Issue in Protein Precipitation and Solid/Liquid Separation. Biopharm. Proc., Aster Publishing Corp., Eugene .
53.Schneider, M., Guillot, C. and Lamy, B. 1981 The affinity precipitation technique. Ann. N. Y. Acad. Sci. 369:257-263.
54.Scopes, R. 1982. Protein Purification: Principles and Practice. Springer-Verlag, Berlin.
55.Scott, J. E. 1998. Secondary and tertiary structures of hyaluronan in aqueous solution. Some biological consequences. Glycoforum: Science of Hyaluronan-2.
56.Senstad, C., and Mattiasson, B. 1989. Affinity precipitation using chitosan as ligand carrier. Biotechnol. Bioeng. 33:216-220.
57.Shah, C. B., and Barnett, S. M. 1992. Swelling behavior of hyaluronic acid gels. J. Appl. Polym. Sci. 45:293-298.
58.Smedsrod, B. 1991. Cellular events in the uptake and degradation of hyaluronan. Adv. Drug Deliv. Rev. 7:265.
59.Sunwoo, H. H., Nakano, T., and Sim, J. S. 1998. Isolation and characterization of proteoglycans from growing antlers of wapiti. Comp. Biochem. Physiol. B- Biochem. Mol. Bio. 124(4):437–442.
60.Toida, T., and Robert, 1996. Detection of glycosaminoglycans as a copper (II) complex in capillary electrophoresis. J., Electrophoresis.17:341-346.
61.Volpi, N. 2000. Hyaluronic acid and chondroitin sulfate unsaturated disaccharides analysis by high-performance liquid chromatography and fluorimetric detection with dansylhydrazine. Anal. Biochem. 277:19 -24.
62.Watt, J. G. 1970. Automatically controlled continuous recovery of plasma protein fractions for clinical use. Vox sang. 18:42-61.
63.Weissmann, B., and Meyer, K. 1954. The Structure of hyaluronic acid and of hyaluronic acid from umbilical cord. J. Am. Chem. Soc. 76: 1753-1757.